It was a pleasure to meet with Prof. Xavier Montalban (Multiple Sclerosis Centre of Catalonia, Vall d’Hebron, Barcelona Hospital Campus, Spain) to discuss the use of ofatumumab as a treatment option for relapsing multiple sclerosis.
The abstract entitled: ‘Effectiveness and Tolerability of Ofatumumab Versus First-line DMTs in Early RMS Patients: Phase 3b STHENOS Study Design’ was presented at the 7th Congress of the European Academy of Neurology – Virtual 2021.
Questions:
- Could you tell us a little about ofatumumab and its mechanism of action? (0:15)
- What are the advantages of ofatumumab compared to current treatment options for relapsing multiple sclerosis (RMS) in adults with active disease? (0:36)
- What have recent clinical trial data taught us about the efficacy and safety of ofatumumab in adults with RMS? (1:15)
Disclosures: Xavier Montalban has received speaking honoraria and/or travel expenses for participation in scientific meetings, and/or has been a steering committee member of clinical trials and/or participated in advisory boards of clinical trials in the past years with Actelion, Alexion, Bayer, Biogen, Bristol-Myers Squibb/Celgene, EMD Serono, Genzyme, Hoffmann-La Roche, Immunic, Janssen Pharmaceuticals, Medday, Merck, Mylan, Nervgen, Novartis, Sanofi-Genzyme, Teva Pharmaceutical, TG Therapeutics, Excemed, MSIF and NMSS.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch
Filmed as a highlight of the EAN Congress, Virtual 2021.
